AEMD on Nasdaq

Aethlon Medical

Logo: aethlonmedical.com³

Price unavailable

Last updated Oct 16, 2026.

Overview

-$7.2MNet income, fiscal 2026⁴

Jan 1, 1999Founded¹

Compare with Co-Diagnostics, Inc., Harvard Apparatus Regenerative Technology, Inc. or Flyte Aviation, Inc., or pick any stock.

TickerAEMD on Nasdaq¹
IndustrySurgical & Medical Instruments & Apparatus¹
HeadquartersSan Diego¹
Websitewww.aethlonmedical.com
Incorporated inNV⁵
Business address11555 Sorrento Valley Road, Suite 203, San Diego, Ca 92121⁵
Filer categoryNon-accelerated filer, Smaller reporting company⁵

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-100.0%Revenue growth, 2024⁶

-211.7%Return on equity⁴

-$10.4MFree cash flow⁷

Financial statements

Revenue⁸⁹¹⁰¹¹⁶$0 in 2024

Operating income⁸⁹¹⁰¹¹⁶⁷-$12.6M in 2024+111% since 2019

Net income⁸⁹¹⁰¹¹⁶⁷-$12.2M in 2024+97% since 2019

Every line of the income statement in the latest annual report, as filed.⁴

Period ending	2026-03-31	2025-03-31
Professional fees	$1.8M	$2.2M
Payroll and related expenses	$2.8M	$3.9M
General and administrative	$2.7M	$3.2M
Total operating expenses	$7.3M	$9.3M
OPERATING LOSS	-$7.3M	-$9.3M
Interest income	$156.5K	$298.1K
Other income	$0	$324.4K
Interest expense	-$14.4K	-$10.1K
Other expense	$0	-$4.7M
Total other income (expense), net	$142.2K	-$4.0M
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	-$7.2M	-$13.4M
Basic net loss per share attributable to common stockholders	-$10.61	-$85.77
Diluted net loss per share attributable to common stockholders	-$10.61	-$85.77
Weighted average number of common shares outstanding - basic	673.9K shares	156.1K shares
Weighted average number of common shares outstanding - diluted	673.9K shares	156.1K shares
OTHER COMPREHENSIVE LOSS	-$15.6K	-$10.2K
COMPREHENSIVE LOSS	-$7.2M	-$13.4M

Total assets⁸⁹¹⁰¹¹⁶⁷$8.2M in 2024+100% since 2019

Total liabilities⁸⁹¹⁰¹¹⁶⁷$2.5M in 2024+36% since 2019

Shareholders’ equity⁸⁹¹⁰⁶⁷⁴$5.8M in 2024+138% since 2019

Cash⁹¹¹⁶⁷$5.4M in 2024−43% since 2020

Every line of the balance sheet in the latest annual report, as filed.⁴

Period ending	2026-03-31	2026-02-28	2025-10-31
Cash and cash equivalents	$5.0M
Deferred offering costs	$211.0K
Prepaid expenses and other current assets	$332.1K
TOTAL CURRENT ASSETS	$5.6M
Property and equipment, net	$356.8K
Operating lease right-of-use asset, net	$307.8K
Patents, net	$0
Restricted cash	$98.9K
Deposits	$0
TOTAL ASSETS	$6.3M
Accounts payable	$384.6K
Due to related parties	$68.2K
Operating lease liability, current portion	$336.7K
Other current liabilities	$657.3K
TOTAL CURRENT LIABILITIES	$1.4M
Operating lease liability, less current portion	$0
TOTAL LIABILITIES	$1.4M
Common stock, $0.001 par value, 100,000,000 shares authorized at March 31, 2026 and 6,000,000 shares authorized at March 31, 2025; 1,570,449 issued and outstanding at March 31, 2026 and 258,531 shares issued and 201,074 outstanding at March 31, 2025	$1.6K
Additional paid-in capital	$180.0M
Accumulated other comprehensive loss	-$32.7K
Accumulated deficit	-$175.1M
TOTAL STOCKHOLDERS EQUITY	$4.9M
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	$6.3M
Common stock, par value	$0.00
Common stock, shares authorized	100.0M shares	100.0M shares	6.0M shares
Common stock, shares issued	1.6M shares
Common stock, shares outstanding	1.6M shares

Cash from operations⁸⁹¹⁰¹¹⁶⁷-$10.1M in 2024+136% since 2019

Capital spending⁸⁹¹⁰¹¹⁶⁷$250.9K in 2024

Free cash flow⁸⁹¹⁰¹¹⁶⁷-$10.4M in 2024+142% since 2019

Every line of the cash flow in the latest annual report, as filed.⁴

Period ending	2026-03-31	2025-03-31
Net loss	-$7.2M	-$13.4M
Depreciation and amortization	$323.7K	$339.6K
Stock-based compensation	$278.5K	$415.2K
Non-cash lease expense	$294.0K	$281.2K
Warrant Inducement Expense	$0	$4.6M
Prepaid expenses and other current assets	$151.6K	$113.9K
Accounts payable and other current liabilities	-$383.4K	-$53.4K
Due to related parties	-$511.3K	$33.1K
Net cash used in operating activities	-$7.0M	-$7.6M
Purchases of property and equipment	-$3.7K	$0
Cash used in investing activities	-$3.7K	$0
Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units	-$10.9K	-$18.9K
Gross proceeds from the issuance of common stock and pre-funded warrants	$6.9M	$4.7M
Payments for offering costs related to equity issuance	-$1.1M	-$1.2M
Proceeds from exercise of warrants standard terms	$0	$2.1M
Proceeds from exercise of warrants induced terms	$848.5K	$2.3M
Commission paid related to warrant inducement	$0	-$154.0K
Legal fees paid related to warrant inducement	$0	-$10.9K
Payments for deferred offering costs related to future equity issuance	-$129.3K	$0
Net cash provided by financing activities	$6.5M	$7.7M
Effect of Exchange Rate on Changes on Cash	$6.5K	-$12.3K
Net (decrease) increase in cash and cash equivalents and restricted cash	-$473.7K	$69.6K
Issuance of shares under vested restricted stock units, net stock option exercises and unvested share issuance for services	$5	$13
Disposal of fully depreciated property	$14.6K	$350.7K
Warrant modification costs	$135.7K	$0
Deferred offering costs not yet paid	$81.7K	$0